Navigation Links
Arena Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
Date:2/27/2013

SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The Boston Marriott Copley Place in Boston, Massachusetts.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com. A replay of the presentation will be available for 30 days following the event. Please connect to Arena's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors to address major therapeutic areas, including cardiovascular, central nervous system, inflammatory and metabolic diseases. BELVIQ® (lorcaserin HCl), Arena's internally discovered drug, was approved by the US Food and Drug Administration in June 2012, and is under review for regulatory approval in additional territories. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Monday, March 4
2. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
3. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
4. Arena Pharmaceuticals and Ildong Pharmaceutical Enter Into Co-Development and License Agreement for Temanogrel, a Novel Agent for Thrombotic Diseases
5. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2012 Financial Results
8. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Tuesday, November 6
9. Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Arena Pharmaceuticals to Present at Upcoming Investor Conferences
11. Arena Pharmaceuticals Announces Second Quarter 2012 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com ... available in its catalogue: The Market ... http://www.reportlinker.com/p02051938/The-Market-for-Medical-Devices-in-EMEA .html The European, Middle Eastern and ... medical devices. As part of its coverage, this ... concentrates on the EMEA medical device markets and ...
(Date:8/20/2014)... Aug. 20, 2014  Quantum Materials Corporation (OTCQB:QTMM) ... of patent families from Bayer Technology Services GmbH, the ... Bayer AG of Leverkusen, Germany ... broad intellectual property protection for advances Quantum ... dot (QD) manufacturing. In addition, the Bayer patents ...
(Date:8/19/2014)... , Aug. 19, 2014 Talyst, a market ... exhibiting at the 2014 NPPA Summer Conference in ... be showcasing its 340B software products and services.   ... splitting solutions, supplying over 400 customers with a variety ... 340B solutions including its latest solution, AutoSplit® Contract Pharmacy ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4Talyst Exhibits at the NPPA Summer Conference 2
... at American Society of Clinical Oncology 2009 Annual Meeting ... , , SAN FRANCISCO, June 2 Medivation, ... presentation of new clinical results from a Phase 1-2 ... castration-resistant prostate cancer (CRPC) patients. The new findings, ...
... , Panel Discussant Focuses on Longer Duration of Remission ... Complete Remissions Achieved with Standard Chemotherapy , , ... MTA: CTIC) announced today that at the poster and ... Section at the 2009 American Society of Clinical Oncology ...
Cached Medicine Technology:Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 2Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 3Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 4Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 2Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 3Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 4Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 5Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment 6
(Date:8/20/2014)... News) -- Pigs, hearts transplanted into baboons survived for ... as previously achieved, researchers report. The work is ... organs to shorten transplant waiting lists. In this ... baboons, abdomens. The genetic engineering and new methods of ... the hearts to survive for more than a year. ...
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... New York, New York (PRWEB) August 20, 2014 ... associated with the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ... Liebhard LLP notes that two U.S. Senators from New ... (FDA) to seek a recall of the devices. In ... Charles Schumer, both Democrats, also implored the agency to ...
(Date:8/20/2014)... contrast to evidence that the amygdala stimulates stress ... Research Center, Emory University have found that the ... during the early development of nonhuman primates. , ... Journal of Neuroscience . , The amygdala is ... important for responses to threatening situations and learning ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3
... Red Compounds Financial Problems, According ... July 14 HealthLeaders-InterStudy, a,leading provider of healthcare ... the hospitals in the Los Angeles market are ... doing relatively well financially,and those that are barely ...
... and Blue Shield companies to,promote workplace wellness programs ... Recognizing that chronic,illness accounts for 75 percent ... on" approach to improving employee health and wellness ... prevention,and management. At a press briefing this morning ...
... of Health,and Hospitals announced its intent to award HMS ... and cost avoidance services,to the state,s Medicaid program. This ... the highest score in a competitive procurement process,for the ... the state, HMS recovered more than,$36 million for the ...
... Zimmer Holdings, Inc.,(NYSE: ZMH ; SWX: ZMH) statement:, ... that Zimmer,s,NexGen(R) knee implant had been recalled. In fact, ... used for minimally invasive,surgeries (MIS) and not the implant ... to a single surgical instrument and that additional,instrumentation options ...
... Bring Better Quality of Care and Improved Business Performance ... ... PITTSBURGH, July 14 Vocollect Healthcare Systems, Inc.,and SouthMed, Inc., ... healthcare market, announce a,strategic partnership, whereby SouthMed will resell AccuNurse,voice-assisted care ...
... Optimism is good for heart health, at least among ... Medical Center researcher Robert Gramling, M.D., D.Sc., found that ... cardiovascular disease actually experienced a three times lower incidence ... data did not support the same conclusion among women. ...
Cached Medicine News:Health News:Fragmented Los Angeles Hospital Market Provides Health Systems with Little Leverage to Negotiate Higher Reimbursement 2Health News:Employers Take Active Role in Promoting Workplace Wellness 2Health News:Employers Take Active Role in Promoting Workplace Wellness 3Health News:Louisiana Department of Health and Hospitals Announces Intent to Award Cost Containment Services Contract to HMS 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 2Health News:Zimmer Holdings Issues Clarification Regarding NexGen Knee System 3Health News:SouthMed, Inc. and Vocollect Healthcare Systems Announce Reseller Agreement 2Health News:Positive thinking is prescription for the heart 2
An enzyme-linked immuno-sorbent assay for the detectionand quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Jerome Halo Traction Units provide optimum immobilization for unstable injuries of the spine. The Generation 80 superstructure is available with either 2-point (serrated disk), or 3-point (flexion/ex...
... Boston Scoliosis Brace™ for neuromuscular ... a lightweight, soft, and easy ... maximum comfort. The Soft ... of non-cracking orthopedic grade copolymer ...
An indirect immunofluorescence antibody test for the qualitative and semi-quantitative detection of endomysial antibodies (EMA) in human serum as an aid in the diagnosis of celiac disease and dermati...
Medicine Products: